Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629327 | 1.00 | PRCP (0.54) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7780443 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7533567 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9659930 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9658679 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9658685 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7782934 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7533568 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7780475 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9659933 | 0.98 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229157-A1 | COMPRESSED CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| EP-2229156-A1 | CHEWING GUM TABLET AND METHOD OF DOSING PHARMACEUTICALLY ACTIVE INGREDIENTS IN SUCH CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| EP-2229158-A1 | COMPRESSED CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| WO-2009080022-A1 | COMPRESSED CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080020-A1 | CHEWING GUM TABLET AND METHOD OF DOSING PHARMACEUTICALLY ACTIVE INGREDIENTS IN SUCH CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080021-A1 | COMPRESSED CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| US-20240238240-A1 | Cannabinoid Pouch | NORDICCAN A/S (DK) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148322-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEARING DISORDERS | GATEWAY BIOTECHNOLOGY, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240218373-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | AIM IMMUNOTECH INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-12016366-B2 | Nicotine pouch composition and pouch comprising such | PHILIP MORRIS PRODUCTS S.A. (CH) | 2024-06-25 | — | — | US | disclosed |
| US-11963944-B2 | Cannabinoid pouch | NORDICCAN A/S (DK) | 2024-04-23 | — | — | US | disclosed |
| WO-2024081864-A1 | INHIBITORS OF NT5C2 AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024076610-A2 | INHIBITORS OF SPNS2 AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20030225031-A1 | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid | NASTECH PHARMACEUTICAL COMPANY INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003000018-A2 | DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-5725852-A | CYTIDINE DIPHOSPHATE CHOLINE ABSORPTION PROMOTER | TAKEDA CHEMICAL INDUSTRIES, LD. (JP) | 1998-03-10 | — | — | US | disclosed |
| US-5482706-A | A PHYSIOLOGICALLY ACTIVE PEPTIDE OR PROTEIN AND A CYTIDINE NUCLEOTIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| EP-0566135-A1 | Transmucosal composition comprising a peptide and a cytidine derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-4954158-A | INHIBIT ETHYLENE PRODUCTION IN PLANTS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1990-09-04 | — | — | US | disclosed |
| WO-1990007260-A2 | 2,3-METHANOPROLINE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1990-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218373-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | ELAVL1, ELAVL3, SYNCRIP | PRCP 2682/4885TLR2 131/4885DPP7 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.